245 related articles for article (PubMed ID: 28676010)
1. KCa3.1 Channel Modulators as Potential Therapeutic Compounds for Glioblastoma.
Brown BM; Pressley B; Wulff H
Curr Neuropharmacol; 2018; 16(5):618-626. PubMed ID: 28676010
[TBL] [Abstract][Full Text] [Related]
2. KCa 3.1-a microglial target ready for drug repurposing?
Dale E; Staal RG; Eder C; Möller T
Glia; 2016 Oct; 64(10):1733-41. PubMed ID: 27121595
[TBL] [Abstract][Full Text] [Related]
3. Repurposing the K
Lee RD; Chen YJ; Nguyen HM; Singh L; Dietrich CJ; Pyles BR; Cui Y; Weinstein JR; Wulff H
Transl Stroke Res; 2024 Jun; 15(3):518-532. PubMed ID: 37088858
[TBL] [Abstract][Full Text] [Related]
4. Senicapoc: Repurposing a Drug to Target Microglia K
Staal RGW; Weinstein JR; Nattini M; Cajina M; Chandresana G; Möller T
Neurochem Res; 2017 Sep; 42(9):2639-2645. PubMed ID: 28364331
[TBL] [Abstract][Full Text] [Related]
5. Functional Roles of the Ca2+-activated K+ Channel, KCa3.1, in Brain Tumors.
D'Alessandro G; Limatola C; Catalano M
Curr Neuropharmacol; 2018; 16(5):636-643. PubMed ID: 28707595
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the potassium channel K
Staal RGW; Khayrullina T; Zhang H; Davis S; Fallon SM; Cajina M; Nattini ME; Hu A; Zhou H; Poda SB; Zorn S; Chandrasena G; Dale E; Cambpell B; Biilmann Rønn LC; Munro G; Mӧller T
Eur J Pharmacol; 2017 Jan; 795():1-7. PubMed ID: 27876619
[TBL] [Abstract][Full Text] [Related]
7. Repurposing the KCa3.1 inhibitor senicapoc for Alzheimer's disease.
Jin LW; Lucente JD; Nguyen HM; Singh V; Singh L; Chavez M; Bushong T; Wulff H; Maezawa I
Ann Clin Transl Neurol; 2019 Apr; 6(4):723-738. PubMed ID: 31019997
[TBL] [Abstract][Full Text] [Related]
8. KCa3.1 channels are involved in the infiltrative behavior of glioblastoma in vivo.
D'Alessandro G; Catalano M; Sciaccaluga M; Chece G; Cipriani R; Rosito M; Grimaldi A; Lauro C; Cantore G; Santoro A; Fioretti B; Franciolini F; Wulff H; Limatola C
Cell Death Dis; 2013 Aug; 4(8):e773. PubMed ID: 23949222
[TBL] [Abstract][Full Text] [Related]
9. Targeting K
Todesca LM; Maskri S; Brömmel K; Thale I; Wünsch B; Koch O; Schwab A
Cell Physiol Biochem; 2021 May; 55(S3):131-144. PubMed ID: 34043300
[TBL] [Abstract][Full Text] [Related]
10. K
Bonito B; Sauter DR; Schwab A; Djamgoz MB; Novak I
Pflugers Arch; 2016 Nov; 468(11-12):1865-1875. PubMed ID: 27752766
[TBL] [Abstract][Full Text] [Related]
11. KCa3.1 Channels and Glioblastoma: In Vitro Studies.
Klumpp L; Sezgin EC; Skardelly M; Eckert F; Huber SM
Curr Neuropharmacol; 2018; 16(5):627-635. PubMed ID: 28786347
[TBL] [Abstract][Full Text] [Related]
12. Increased Interleukin-10 Expression by the Inhibition of Ca
Ohya S; Matsui M; Kajikuri J; Endo K; Kito H
J Pharmacol Exp Ther; 2021 Apr; 377(1):75-85. PubMed ID: 33504590
[TBL] [Abstract][Full Text] [Related]
13. Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease.
Paka L; Smith DE; Jung D; McCormack S; Zhou P; Duan B; Li JS; Shi J; Hao YJ; Jiang K; Yamin M; Goldberg ID; Narayan P
World J Gastroenterol; 2017 Jun; 23(23):4181-4190. PubMed ID: 28694658
[TBL] [Abstract][Full Text] [Related]
14. The potassium channel KCa3.1 constitutes a pharmacological target for neuroinflammation associated with ischemia/reperfusion stroke.
Chen YJ; Nguyen HM; Maezawa I; Grössinger EM; Garing AL; Köhler R; Jin LW; Wulff H
J Cereb Blood Flow Metab; 2016 Dec; 36(12):2146-2161. PubMed ID: 26661208
[TBL] [Abstract][Full Text] [Related]
15. Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications.
Wulff H; Kolski-Andreaco A; Sankaranarayanan A; Sabatier JM; Shakkottai V
Curr Med Chem; 2007; 14(13):1437-57. PubMed ID: 17584055
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the K
Organ L; Bacci B; Koumoundouros E; Kimpton WG; Samuel CS; Nowell CJ; Bradding P; Roach KM; Westall G; Jaffar J; Snibson KJ
Am J Respir Cell Mol Biol; 2017 Apr; 56(4):539-550. PubMed ID: 28060543
[TBL] [Abstract][Full Text] [Related]
17. Altered K
Seo CH; Cui HS; Kim JB
Transl Res; 2021 Oct; 236():133-146. PubMed ID: 33905948
[TBL] [Abstract][Full Text] [Related]
18. Role of KCa3.1 Channels in Modulating Ca
Catacuzzeno L; Franciolini F
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30274242
[TBL] [Abstract][Full Text] [Related]
19. Role of KCa3.1 Channels in CNS Diseases: A Concise Review.
Sugunan S; Nampoothiri SS; Garg T; Krishnamurthy RG
CNS Neurol Disord Drug Targets; 2016; 15(10):1299-1305. PubMed ID: 27549144
[TBL] [Abstract][Full Text] [Related]
20. The Ca2+-activated K+ channel KCNN4/KCa3.1 contributes to microglia activation and nitric oxide-dependent neurodegeneration.
Kaushal V; Koeberle PD; Wang Y; Schlichter LC
J Neurosci; 2007 Jan; 27(1):234-44. PubMed ID: 17202491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
